The US Food and Drug Administration (FDA) has approved United States-based Alnylam Pharmaceuticals' GIVLAARI (givosiran) injection for subcutaneous use for the treatment of adults with acute hepatic porphyria (AHP), a family of ultra-rare, genetic diseases characterised by debilitating, potentially life-threatening attacks, it was reported yesterday.
The product received approval in less than four months after acceptance of the NDA and was based on positive results from the ENVISION Phase 3 study, a randomised, double-blind, placebo-controlled, multinational study of 94 patients with acute hepatic porphyria, at 36 study sites in 18 countries – the largest ever interventional study conducted in AHP. In ENVISION, AHP patients on GIVLAARI experienced 70% (95% CI: 60%, 80%) fewer porphyria attacks compared to placebo. The product also resulted in a similar decrease in intravenous hemin use, and decrease in urinary aminolevulinic acid and urinary porphobilinogen.
The product is likely to be offered for shipment to healthcare providers in the United States by the end of 2019.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial